Biocon's Yesintek® Autoinjector Gets Health Canada Approval

Biocon Limited's Canadian subsidiary has received Notice of Compliance (NOC) from Health Canada for its Yesintek® (ustekinumab) Autoinjector Pen in 45 mg/0.05 mL and 90 mg/mL strengths. This follows earlier approvals for prefilled syringes and vials. The autoinjector offers a new treatment option for patients in Canada, not available with the originator product, allowing for customized treatment approaches. Yesintek® is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. This approval expands Biocon's immunology product portfolio in Canada and reinforces its commitment to making affordable medicines accessible globally.